See more : Almunda Professionals N.V. (NOVI.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Gemina Laboratories Ltd. (GLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gemina Laboratories Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Asia Sejahtera Mina Tbk (AGAR.JK) Income Statement Analysis – Financial Results
- Bailador Technology Investments Limited (BTI.AX) Income Statement Analysis – Financial Results
- Leader Capital Holdings Corp. (LCHD) Income Statement Analysis – Financial Results
- Kolmar Korea Holdings Co., Ltd. (024720.KS) Income Statement Analysis – Financial Results
- Presidio Property Trust, Inc. (SQFTP) Income Statement Analysis – Financial Results
Gemina Laboratories Ltd. (GLABF)
About Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 93.37K | 50.28K | 43.83K | 12.09K |
| Gross Profit | -93.37K | -50.28K | -43.83K | -12.09K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.48M | 4.15M | 2.71M | 508.26K |
| General & Administrative | 2.14M | 1.80M | 1.99M | 141.23K |
| Selling & Marketing | 462.32K | 0.00 | 0.00 | 125.11K |
| SG&A | 2.61M | 1.80M | 1.99M | 125.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.09M | 5.98M | 4.73M | 633.51K |
| Cost & Expenses | 5.09M | 5.98M | 4.73M | 645.60K |
| Interest Income | 0.00 | 1.10K | 0.00 | 0.00 |
| Interest Expense | 19.26K | 0.00 | 539.00 | 2.47K |
| Depreciation & Amortization | 21.71K | 50.28K | 43.83K | 12.09K |
| EBITDA | -5.18M | -5.93M | -4.69M | -633.51K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -5.98M | -4.73M | -645.60K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -130.91K | 280.97K | 175.98K | -251.41K |
| Income Before Tax | -5.22M | -5.98M | -4.73M | -834.15K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -117.61K | -184.65K | 0.00 |
| Net Income | -5.22M | -5.98M | -4.73M | -834.15K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.10 | -0.10 | -0.02 |
| EPS Diluted | -0.07 | -0.10 | -0.10 | -0.02 |
| Weighted Avg Shares Out | 72.45M | 60.19M | 47.66M | 50.24M |
| Weighted Avg Shares Out (Dil) | 72.45M | 60.19M | 47.66M | 50.24M |
Gemina Laboratories Announces Private Placement
Gemina Laboratories Strategic Update
Source: https://incomestatements.info
Category: Stock Reports